Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Work In Process (2021 - 2024)

Historic Work In Process for RedHill Biopharma (RDHL) over the last 4 years, with Q4 2024 value amounting to $308000.0.

  • RedHill Biopharma's Work In Process rose 3218.88% to $308000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $308000.0, marking a year-over-year increase of 3218.88%. This contributed to the annual value of $308000.0 for FY2024, which is 3218.88% up from last year.
  • Per RedHill Biopharma's latest filing, its Work In Process stood at $308000.0 for Q4 2024, which was up 3218.88% from $233000.0 recorded in Q4 2023.
  • Over the past 5 years, RedHill Biopharma's Work In Process peaked at $5.2 million during Q4 2021, and registered a low of $233000.0 during Q4 2023.
  • Its 4-year average for Work In Process is $2.0 million, with a median of $1.3 million in 2022.
  • As far as peak fluctuations go, RedHill Biopharma's Work In Process plummeted by 9023.06% in 2023, and later skyrocketed by 3218.88% in 2024.
  • RedHill Biopharma's Work In Process (Quarter) stood at $5.2 million in 2021, then tumbled by 54.09% to $2.4 million in 2022, then plummeted by 90.23% to $233000.0 in 2023, then soared by 32.19% to $308000.0 in 2024.
  • Its last three reported values are $308000.0 in Q4 2024, $233000.0 for Q4 2023, and $2.4 million during Q4 2022.